I actually have a better solution for PTOI, one that I've
I actually have a better solution for PTOI, one that I've offered before as well.
If Mr. Heddle can show me strong evidence that a processor can produce 230 bbl/day of WTI-$3 oil at a cost of under $10/bbl, I will personally step up and buy a processor myself. Guaranteed sale...just show me strong evidence of that 132% annual return that the processor can supposedly produce based on PTOI's previous official claims.
So during Mr. Heddle's three and a half year sales effort, I wonder how many customers were shown strong evidence of that impressive 132% return on capital provided by PTOI's processor...yet declined to buy a processor. Maybe the numbers are still just too incredible...maybe PTOI should slap a $15,000,000 price tag on the processors so customers don't feel like it's too good to be true.
...or maybe investors should set aside some time and entertain the notion that Mr. Bordynuik and Mr. Heddle aren't the honest businessmen that investors feel they are.
The notion that the first customer is just so hard to find is ludicrous. Show people where the money is and they will come running. As I said, PTOI has an immediate customer in me provided they can back up their claims and I'm a person who believes they're swindlers. If a skeptic is willing to immediately buy a processor if shown evidence of value, why are other customers so hard to find??
Third and last post.
Plastic2Oil, Inc. (PTOI) Stock Research Links
Yes, I understand your penny stock also is the real deal, created with the inventiveness of Edison and destined to be the next Microsoft. Yes, I understand that the delays are also only because your company is making their product and/or technology even more revolutionary.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
ZEISS Sets Sights on China’s Myopia Epidemic They're calling myopia a public health crisis in China, and if you've seen the statistics, that's no exaggeration. Enter ZEISS Medical Technology, angling for a piece of the pie with their newly NMPA-approved PT LUNANA phakic intraocular lens. This is more than just another medical product, folks. It's a strategic entry into...
Continue Reading
A Strong Quarter Despite Some Knocks It ain't every day you see a company like Keenova Therapeutics clocking solid top-line growth, despite battling the waves of operational losses. Now, don't get me wrong; I ain't swooning over their near $96 million loss from continuing operations, but let me give credit where it's due—those sales numbers popped impressive. Pillars of...
Continue Reading
Graphene Making Waves in Defense Fresh off the press, folks. First Graphene Limited is struttin' onto the US defense scene with a repeat order for its PureGRAPH®—a big deal in the realm of electrically conductive inks. The tally comes to around A$35,000 in an order from a longtime American customer. We're talking about inks that print circuits, sensors, and more,...
Continue Reading
Hunting for the Perfect Gift? Look No Further The holiday hustle and bustle inevitably sparks one of the annual dilemmas: What on earth should you buy those grandkids of yours? No need to get all twisted up this season. Enter ZestYears, the savvy go-to guide for grandparents who want to nail gift-giving without breaking a sweat or the bank. These folks, based out of...
Continue Reading
If you've ever punched numbers on car values, you've probably bumped into Kelley Blue Book. This icon in vehicle valuation is marking its 100th birthday with a bang—road-tripping across Route 66 to sprinkle some joy across the dusty roads of history. Nostalgia Meets the Open Road The legendary Route 66 is not just the backdrop but the beating heart of this centennial...
Continue Reading
Building Bridges Between Work and Home Well, it’s about time someone threw in a lifeline to those drowning in Florida’s housing crisis. Tampa General Hospital, teaming up with The Michaels Organization, is setting the stage with 'The Linden': a solution pitched smack dab into the heart of affordability woes. This isn't your run-of-the-mill press release fluff. They've...
Continue Reading
Hexnode XDR: A Game Changer for MacOS Threats Ever heard of Hexnode? Well, today's chat is all about them beefing up their XDR platform. They’ve sagely added support for macOS—finally given the platform some love alongside Windows. It's about time! This move is a big win for everyone whose daily grind depends on keeping threats at bay across platforms. We’re talking...
Continue Reading
Partnership to Expand Digital Asset Liquidity Looks like Caladan and NextBlock just threw their hats in the ring to shake up South Korea’s institutional digital asset market. These two big guns have cooked up a strategic collaboration, aiming to bring more global liquidity into the mix. Dive into what this means for the digital asset scene in South Korea. Why This Move...
Continue Reading
Blazing a New Trail in Automotive Excellence Who would've thought rubber on road could hit a jaw-dropping 503.17 km/h (312.65 mph)? Giti Tire just broke the mold, etching its name into the history books with the Guinness World Records™ title for their GitiSport e.GTR2 Pro tires. This isn't just about speed—it's about engineering marvel and pushing boundaries in...
Continue Reading
Why Your Vision Might Be Blurry: It's Not Always Simple Dr. Spencer Franz isn’t just another face behind an optometry chart. He’s tackling a topic as blurry as it is relatable—your vision. You'd think a simple tweak of your glasses script might do the trick, but surprise, surprise, vision issues are sneakier than that. Changes in prescriptions are a dime a dozen,...
Continue Reading
Top 5 Most Recently Viewed Articles
Assessing Cresco Labs: A Promising Investment Prospect With the cannabis market continuing to evolve, Cresco Labs Inc. stands out as an intriguing option for investors. Despite a backdrop of flat earnings and ongoing market challenges, analysts emphasize that Cresco (CRLBF) is holding the line as an "Overweight" stock. A recent analysis reveals Cresco's substantial...
Continue Reading
Context Therapeutics Releases First Quarter 2025 Financial Results Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, made significant strides in Q1 2025, especially with its two product candidates, CTIM-76 and CT-95, currently in Phase 1 clinical trials. As of March 31, 2025, the company reported...
Continue Reading
Capricor Under the Spotlight: FDA and SEC Concerns Ah, Capricor Therapeutics, Inc. (NASDAQ: CAPR)—a tale of high stakes and even higher expectations now hanging by a very taut thread. Investors are feeling the heat as the U.S. Food and Drug Administration (FDA) presses pause on Capricor's plans, and the courtroom drama unfolds with a securities class action looming over...
Continue Reading
Wood Partners Begins Construction on Alta Flatirons The 251-unit apartment community is one of the last remaining parcels of the Downtown Superior Masterplan. Overview of Alta Flatirons National multifamily developer Wood Partners has officially commenced the development of Alta Flatirons, a significant project located in a suburb near Boulder. This community, which will...
Continue Reading
Adobe Unveils Exciting New AI-Driven Marketing Tools Adobe Systems Incorporated (NASDAQ: ADBE) has just rolled out a game-changing suite of updates to its Adobe Experience Cloud services. These innovations are designed to help brands enhance the performance of their AI-generated marketing content significantly. With a focus on advanced analytics and the ability to...
Continue Reading